Fortis Healthcare share price
NSE: FORTISBSE: 532843Healthcare ServicesMid Cap
Fortis Healthcare Limited · Formerly Fortis Healthcare (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2007
Last close ₹768.15up ₹13.25 (1.76%)BSE ₹769.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹754.90.
30 Oct: open ₹754.90, high ₹768.15, low ₹745.00
52-week range of traded prices to 30 Oct 2026
₹704.95Low, 23 Oct 2026₹1,057.45High, 30 Oct 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,992 Cr156th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 55.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.13%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.28
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,56,10356.9% delivered
About Fortis Healthcare
Fortis Healthcare Limited runs hospitals in India that offer secondary, tertiary and quaternary care, from routine hospital treatment to the most complex specialist procedures, in specialties such as cardiac sciences, oncology, neurosciences and orthopaedics.1 Through its subsidiary Agilus Diagnostics, it also runs a chain of diagnostic centres.23
Its hospitals are grouped in clusters in the National Capital Region, Punjab, Bengaluru, Kolkata and Mumbai.4 It also runs hospitals owned by others under O&M agreements (contracts to run a hospital that someone else owns), including, since 23 Jul 2025, 5 hospitals and a clinic of Gleneagles Healthcare, a company of its parent group, IHH Healthcare.5
It was incorporated in 1996, with its registered office in Mohali, Punjab.26 On 13 Nov 2018, IHH Healthcare Berhad of Malaysia took a 31.10% stake and became the controlling shareholder.23 In April 2025 it bought the 'Fortis' brand and trademarks at an auction ordered by the Delhi High Court, with a bid of ₹200 crore.78
Its promoter is Northern TK Venture Pte Ltd, an indirect wholly owned subsidiary of IHH, which held 31.17% of the shares at 31 Mar 2026.9110
Fortis Healthcare key points
Results
- In the quarter to Jun 2026, consolidated revenue was ₹2,545 crore, up 17.5% on a year earlier. Operating EBITDA (earnings before interest, tax, depreciation and amortisation), before about ₹31 crore of employee share option costs, was ₹568 crore, a 22.3% margin, up 15.8%.1112
- In the year to Mar 2026, consolidated revenue grew 17.3% to ₹9,128 crore, and reported EBITDA rose 29.1% to ₹2,136 crore, a 23.4% margin.131415
- Consolidated profit after tax for the quarter, excluding one-off items, was ₹263 crore, up 3.6%. For the year to Mar 2026 it was ₹1,064 crore, including a net one-off loss of ₹22.2 crore, against ₹809 crore a year earlier.1617
- Net debt (borrowings minus cash) was ₹2,233 crore at 30 Jun 2026, or 0.21 times shareholders' equity.18
Business segments
- Hospitals (85% of consolidated revenue in the year to Mar 2026). Revenue grew 19% to ₹2,187 crore in the quarter to Jun 2026, against ₹1,838 crore. Operating EBITDA rose 15.9% to ₹471 crore, a 21.5% margin against 22.1%; excluding newly acquired or commissioned hospitals, the margin was about 22%, similar to a year earlier.1920
- Diagnostics (Agilus Diagnostics). Gross revenue (before deducting sales within the group) grew 10% to ₹407 crore in the quarter to Jun 2026, against ₹369 crore. The operating EBITDA margin on gross revenue was 23.9%, against 23.0%.21
- Diagnostics network. Agilus has over 400 laboratories and 4,400 customer touchpoints across 27 states. In the year to Mar 2026 it served over 16.8 million patients and ran 40.8 million tests, against 39.2 million a year earlier.22
Revenue mix
- Share of hospital revenue, largest lines2324Hospital revenue from the focus specialties (cardiac sciences, oncology, orthopaedics, neurosciences, renal sciences and gastroenterology) grew 16.9% and made up 62% of hospital revenue.
Item quarter to Jun 2026 quarter to Jun 2025 Cardiac sciences 16.6% 16.9% Oncology 14.4% 16.4% Orthopaedics 10.3% 9.9% Neurosciences 8.6% 8.1% Renal sciences 7.3% 6.9% Gastroenterology 4.7% 5.1% Outpatient services 14.4% 13.9% Other inpatient services 16.1% 15.4% - Share of hospital revenue by who pays2526
Item quarter to Jun 2026 quarter to Jun 2025 Insurers, through third-party administrators (TPAs) 37.2% 37.1% Indian patients paying themselves 33.3% 33.6% Government and public sector companies 8.4% 8.7% International patients 7.5% 7.9% Ex-servicemen's health scheme (ECHS) 7.1% 7.3% Central Government Health Scheme (CGHS) 5.2% 4.3%
Hospital network
- As of 16 Sep 2026, the company ran 36 healthcare facilities across 12 states with over 6,150 operational beds.27
- In its presentation of 6 Aug 2026, the company said about 1,200 of its beds were run under O&M agreements, and that it had over 8,100 doctors and 9,500 nurses, including trainees.28
- In the quarter to Jun 2026, hospital bed occupancy was 68.7%, against 69.0% a year earlier, and average revenue per occupied bed (ARPOB) was ₹2.71 crore a year, up 2.6% from ₹2.64 crore.29
- In the year to Mar 2026 its clinicians performed 75,900 cardiac procedures, over 1,100 transplants and more than 10,200 robotic surgeries, and its surgical robots across the group rose to 19.3031
Expansion and capital spending
- The company stated in its annual report for the year to Mar 2026 that it plans to add around 1,800 beds at existing hospitals by Mar 2030, with major projects under way at Fortis Memorial Research Institute (FMRI), Shalimar Bagh, Amritsar and Mohali.323334
- In July 2025 the company bought the 228-bed Shrimann Superspecialty Hospital in Jalandhar for ₹462 crore, and in January 2026 the 125-bed People Tree Hospital in Bengaluru, with adjacent land, for ₹430 crore.35
Recent events
- On 16 Sep 2026, subsidiary Fortis Hospotel agreed to provide healthcare services for 29 years, and a phased loan, to a charitable society's planned 400+ bed hospital in Ashok Vihar, Delhi, expected to open in 3 to 4 years, subject to approvals.3637
- On 3 Jul 2026, the company announced that it had signed an O&M agreement with Dion Group for a 300-bed hospital to be built in Cuttack, its first major presence in Odisha.38
Litigation and regulatory matters
- On 31 Aug 2026, on applications by Daiichi Sankyo, the Delhi High Court ordered a forensic audit of how the former promoters' shares were sold off, the change in control and the roles of banks and the company. It imposed no liability on the company.39
- As of its annual report of 17 Jul 2026, the Serious Fraud Investigation Office (SFIO), a government fraud investigator, was investigating the company and its subsidiaries, and the company was pursuing recovery of about ₹397.12 crore from its former promoters and their related entities.4041
- In its exchange filing of 1 Apr 2026, the company said the income tax authority raised a demand of ₹149.12 crore on subsidiary Fortis Hospitals for the assessment year 2021-22, and that it was evaluating an appeal. No later outcome is given.42
Last updated
All 42 sources, each with its page
- 1. Annual report, 17 Jul 2026, page 62
- 2. Annual report, 17 Jul 2026, page 331
- 3. Annual report, 17 Jul 2026, page 266
- 4. Annual report, 17 Jul 2026, page 35
- 5. Annual report, 17 Jul 2026, page 64
- 6. Annual report, 17 Jul 2026, page 3
- 7. Annual report, 17 Jul 2026, page 82
- 8. Annual report, 17 Jul 2026, page 68
- 9. Annual report, 17 Jul 2026, page 6
- 10. Annual report, 17 Jul 2026, page 372
- 11. Investor presentation, 6 Aug 2026, page 7
- 12. Investor presentation, 6 Aug 2026, page 27
- 13. Annual report, 17 Jul 2026, page 45
- 14. Annual report, 17 Jul 2026, page 44
- 15. Annual report, 17 Jul 2026, page 37
- 16. Investor presentation, 6 Aug 2026, page 7
- 17. Annual report, 17 Jul 2026, page 62
- 18. Investor presentation, 6 Aug 2026, page 15
- 19. Investor presentation, 6 Aug 2026, page 8
- 20. Annual report, 17 Jul 2026, page 194
- 21. Investor presentation, 6 Aug 2026, page 12
- 22. Annual report, 17 Jul 2026, page 50
- 23. Investor presentation, 6 Aug 2026, page 17
- 24. Investor presentation, 6 Aug 2026, page 11
- 25. Investor presentation, 6 Aug 2026, page 18
- 26. Investor presentation, 6 Aug 2026, page 11
- 27. Exchange filing, 16 Sep 2026, page 3
- 28. Investor presentation, 6 Aug 2026, page 4
- 29. Investor presentation, 6 Aug 2026, page 8
- 30. Annual report, 17 Jul 2026, page 38
- 31. Annual report, 17 Jul 2026, page 194
- 32. Annual report, 17 Jul 2026, page 62
- 33. Annual report, 17 Jul 2026, page 196
- 34. Annual report, 17 Jul 2026, page 41
- 35. Annual report, 17 Jul 2026, page 62
- 36. Exchange filing, 16 Sep 2026, page 2
- 37. Exchange filing, 16 Sep 2026, page 1
- 38. Exchange filing, 3 Jul 2026, page 2
- 39. Exchange filing, 1 Sep 2026, page 1
- 40. Annual report, 17 Jul 2026, page 82
- 41. Annual report, 17 Jul 2026, page 64
- 42. Exchange filing, 1 Apr 2026, page 2
Results
Consolidated; ₹ crore.Fortis Healthcare quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +17.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +20.7%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,545 Crup 7.63%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹273 Crup 0.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.7%
Revenue by quarter
Peak revenue ₹2,545 Cr, quarter to Jun 2026; lowest ₹1,928 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 | 2,265 | 2,365 | 2,545 |
| Net profit | 193 | 254 | 188 | 267 | 329 | 197 | 271 | 273 |
| Net margin | 9.7% | 13.2% | 9.4% | 12.3% | 14.1% | 8.7% | 11.5% | 10.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹9,128 Crup 17.28%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,064 Crup 31.48%
- Net margin
- 11.7%
Revenue by year
Peak revenue ₹9,128 Cr, year to Mar 2026; lowest ₹4,030 Cr, year to Mar 2021
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 3 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 9,128 |
| Net profit | 479 | −934 | −224 | 91 | −56 | 790 | 633 | 645 | 809 | 1,064 |
| Net margin | 10.5% | −20.5% | −5.0% | 2.0% | −1.4% | 13.8% | 10.1% | 9.4% | 10.4% | 11.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- HealthcareHealthcare, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹7,773 Crup 19.07%83.6%
- DiagnosticsDiagnostics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,527 Crup 8.52%16.4%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.Fortis Healthcare PE ratio and valuation
Price to earnings
At or below today's level on 30% of 1,240 trading days over the last 5 years.
LowestHighest
Its median64.45Industry median40.93
Price to book
At or below today's level on 74% of 1,895 trading days since Nov 2018.
LowestHighest
Its median3.36Industry median4.37
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 80% of 2,475 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.25%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +14.0% | +34.5% | −15.4% | 0.1% |
| 3 years | +45.3% | +20.9% | +20.0% | 0.2% |
| 5 years | +32.1% | – | – | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2025.
Mutual fund holdings
271 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 107 of the 148 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 271 funds holding Fortis Healthcare
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 10
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 73
- CutCut. Funds that held fewer shares than at the end of the month before.
- 75
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 110
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 16
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 3,17,01,862 | 2.40% | ₹2,441.0 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 3,01,61,426 | 3.49% | ₹2,322.4 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 1,65,00,100 | 2.53% | ₹1,270.5 Cr |
 Axis Midcap FundAxis Mutual Fund | 1,13,75,762 | 2.61% | ₹875.9 Cr |
 DSP Midcap FundDSP Mutual Fund | 63,94,812 | 2.53% | ₹492.4 Cr |
| HDFC Small Cap FundHDFC Mutual Fund | 50,00,176 | 0.94% | ₹385.0 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 47,33,349 | 1.28% | ₹364.5 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 47,00,000 | 1.18% | ₹361.9 Cr |
 Edelweiss Mid Cap FundEdelweiss Mutual Fund | 41,81,418 | 1.67% | ₹322.0 Cr |
| DSP Large & Mid Cap FundDSP Mutual Fund | 35,72,023 | 1.59% | ₹275.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Fortis Healthcare competitors and peers
Hospital, 40 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Fortis Healthcare in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Apollo Hospitals EnterpriseAPOLLOHOSP | 1,21,469 | 58.13 | 12.81 | +17.2% | +32.8% | 23.6% | 19.9% | 0.24% |
| Manipal Health EnterprisesMANIPALHOS | 88,018 | – | – | – | – | – | – | 0.00% |
 Max Healthcare InstituteMAXHEALTH | 83,705 | 60.61 | 7.39 | +15.2% | +1.8% | 12.9% | 12.7% | 0.23% |
 Aster DM Quality CareASTERDM | 59,374 | 186.31 | – | +15.7% | +0.2% | 8.0% | 12.4% | 0.44% |
 Narayana HrudayalayaNH | 35,154 | 40.93 | 7.03 | +71.4% | +1.6% | 19.0% | 13.1% | 0.26% |
 Global HealthMEDANTA | 34,155 | 61.41 | 8.62 | +21.3% | +4.1% | 15.1% | 14.2% | 0.04% |
 Krishna Institute of Medical SciencesKIMS | 29,476 | 144.14 | 13.12 | +30.9% | −46.2% | 9.3% | 8.7% | 0.00% |
 Dr. Agarwal's Health CareAGARWALEYE | 16,143 | 108.80 | 7.97 | – | – | 7.6% | 14.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Fortis Healthcare dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, in 4 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 25 Jul 2025 | Final | ₹1.00 |
| 24 Jul 2024 | Final | ₹1.00 |
| 20 Jul 2023 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Fortis Healthcare announcements
Oct 2026
29 Oct · Analysts
12 Oct · Updates
Sep 2026
29 Sep · General Updates
Fortis Healthcare share price by year
Each calendar year to 2025.Fortis Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 884.00 | +22.8% | 1,097.90 | 581.20 |
| 2024 | 719.85 | +71.7% | 725.80 | 380.80 |
| 2023 | 419.20 | +46.5% | 419.20 | 250.60 |
| 2022 | 286.10 | −3.8% | 321.05 | 226.05 |
| 2021 | 297.30 | +91.6% | 297.30 | 155.75 |
| 2020 | 155.20 | +17.7% | 164.45 | 113.50 |
| 2019 | 131.90 | −6.1% | 158.60 | 116.25 |
| 2018 | 140.50 | −12.4% | 165.60 | 114.20 |
| 2017 | 160.45 | −11.3% | 226.80 | 125.10 |
| 2016 | 180.85 | +0.4% | 193.80 | 150.40 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 760.50 | 761.00 | 750.35 | 754.90 | 754.63 | 7,53,813 | 59.2% |
| 28 Oct 2026 | 734.90 | 762.90 | 726.85 | 759.50 | 754.59 | 14,44,496 | 45.3% |
| 27 Oct 2026 | 733.45 | 747.25 | 725.90 | 736.50 | 736.43 | 25,14,312 | 63.3% |
| 26 Oct 2026 | 714.00 | 734.70 | 705.40 | 734.70 | 721.42 | 13,65,215 | 45.5% |
| 23 Oct 2026 | 726.65 | 728.65 | 704.95 | 712.90 | 712.60 | 9,87,090 | 51.8% |
| 22 Oct 2026 | 723.50 | 726.65 | 710.80 | 726.65 | 720.78 | 12,61,211 | 61.2% |
| 21 Oct 2026 | 735.00 | 741.55 | 721.00 | 729.00 | 729.26 | 7,03,314 | 52.0% |
| 19 Oct 2026 | 737.25 | 745.15 | 731.80 | 737.80 | 739.97 | 10,76,545 | 61.7% |
| 16 Oct 2026 | 749.00 | 749.00 | 734.15 | 736.50 | 739.28 | 11,41,924 | 59.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Open offer history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 18 Aug 2009 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- FORTIS
- BSE code
- 532843
- ISIN
- INE061F01013
- Industry
- Healthcare Services
- Website
- www.fortishealthcare.com
- CIN
- L85110PB1996PLC045933
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1996
- Registered office
- Fortis Hospital, Sector 62, Phase - VIII, Mohali 160062, Punjab
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index